The Peptide CDMO Market is gaining importance as pharmaceutical and biotechnology companies increasingly outsource peptide development and manufacturing to specialized contract development and manufacturing organizations. WiseGuyReports estimates the market at USD 10.29 billion in 2024 and projects it to reach USD 27.2 billion by 2032, with a reported CAGR of 12.93%. Rising demand for peptide-based therapeutics, advances in synthesis technologies, and the expanding outsourcing model are central factors supporting this growth.
Pharmaceutical applications represent the largest demand area, accounting for around 58% of market revenue in 2023. Peptides are being explored across therapeutic areas including oncology, diabetes, autoimmune disorders, and other chronic conditions. As drug developers expand peptide pipelines, CDMOs can provide specialized capabilities for synthesis, purification, formulation, and related manufacturing activities.
Technology development is also reshaping the competitive environment. Solid Phase Peptide Synthesis (SPPS) accounted for more than 55% of global revenue in 2023, reflecting its established role in producing peptides efficiently and at scale. Liquid Phase Peptide Synthesis remains important, while microwave-assisted synthesis and automated peptide synthesizers are gaining attention because of their potential to improve production speed, consistency, and throughput.
The shift toward outsourcing allows pharmaceutical companies to concentrate resources on discovery and clinical development while accessing specialized manufacturing expertise. This trend is particularly relevant for complex peptide programs that require advanced synthesis and purification capabilities.
As peptide therapeutics become more prominent, CDMOs offering integrated development-to-manufacturing services may be positioned to capture increasing demand. The combination of technology investment, specialized expertise, and expanding pharmaceutical outsourcing is expected to remain a key foundation for market growth.
